secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001654954-22-015138
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin Q1 FY2023 net loss $8.3M; Vyleesi revenue up 445% YoY; PL9643 topline Q2 2023
--------------------------------------------------------------------------------

- Net loss of $8.3M ($0.86/share) vs $7.1M ($0.75/share) in prior year quarter.
- Vyleesi net product revenue $869,654, up 445% YoY; prescriptions dispensed up 17% QoQ.
- Phase 3 PL9643 for dry eye: DMC recommends 350-patient study; topline data expected Q2 2023.
- Phase 2 oral PL8177 for ulcerative colitis commenced; interim analysis Q1 2023, topline Q3 2023.
- Cash $21.2M as of Sep 30; closed $10M offering in Nov 2022; operating cash runway through CY 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495422015138/0001654954-22-015138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495422015138/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-015138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer